Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

April 28, 2025

Primary Completion Date

October 31, 2029

Study Completion Date

October 31, 2029

Conditions
Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Interventions
DRUG

SX-682

SX-682 is supplied as 100mg film coated tablets.

DRUG

Apalutamide

Apalutamide is supplied as 60mg film coated tablets.

Trial Locations (4)

CH6500

NOT_YET_RECRUITING

Oncology Institute of Southern Switzerland, Bellinzona

BT9 7AB

NOT_YET_RECRUITING

Belfast Health and Social Care Trust, Belfast

CB2 0QQ

NOT_YET_RECRUITING

Cambridge University Hospitals NHS Foundation Trust, Cambridge

SM2 5PT

RECRUITING

The Royal Marsden NHS Foundation Trust - Drug Development Unit, Sutton

All Listed Sponsors
collaborator

Prostate Cancer UK

OTHER

collaborator

Janssen Pharmaceutica N.V., Belgium

INDUSTRY

collaborator

Oncology Institute of Southern Switzerland

OTHER

collaborator

Syntrix Biosystems, Inc.

INDUSTRY

collaborator

Royal Marsden NHS Foundation Trust

OTHER

collaborator

Cambridge University Hospitals NHS Foundation Trust

OTHER

collaborator

Belfast Health and Social Care Trust

OTHER

collaborator

Institute of Oncology Research (IOR)

UNKNOWN

lead

Institute of Cancer Research, United Kingdom

OTHER